In the BxPC-3 xenograft model here, the VEGFA-and-NRP1 dual-targeting bispecific antibody (IDB0076) significantly retarded the tumor growth and tumor blood vessel formation as compared with the VEGFA-blocking monospecific antibody bevacizumab (Figure 3). Here, VEGFA is linked to neoplasm.